Since October, personnel changes of pharmaceutical enterprises have been frequent, and industrial reform has entered a critical period

[industry trends of pharmaceutical network] on October 29, Yantai Dongcheng Pharmaceutical Co., Ltd announced that the company had received the resignation submitted by Bai Xinghua, deputy general manager and Secretary of the board of directors of the company, and Bai Xinghua resigned as deputy general manager and Secretary of the board of directors for personal reasons This is also a new event of executives' resignation since the winter of the whole industry In fact, since October, several listed companies have announced the resignation of directors and senior executives, including personal reasons and job transfer For a while, the reasons behind the phenomenon of senior managers' turnover in the pharmaceutical industry have aroused widespread concern in the industry Some insiders said that with the nationwide expansion and landing of "4 + 7" volume procurement, the reform of the pharmaceutical industry has also entered a critical stage, and the upgrading and transformation of domestic pharmaceutical enterprises in management and marketing are on the agenda Therefore, during this period of time, personnel changes and structural adjustments naturally become more frequent On October 12, several senior managers of pharmaceutical companies resigned Zhuhai Theron Pharmaceutical Co., Ltd announced that the board of directors of the company had recently received a written resignation report from Ms Tang Lin, the director and deputy general manager of the company For personal reasons, Ms Tang Lin applied to resign from the position of deputy general manager of the company On the same day, Ningbo Minova Pharmaceutical Co., Ltd announced that the board of directors of the company had received the written resignation report of Ms Sun Yan, the Secretary of the board of directors of the company, on October 11, 2019 Ms Sun Yan resigned as the Secretary of the board of directors due to work reasons, and continued to serve as the director and financial director of the company after resignation On October 18, the board of directors of the company received the resignation report from Yu Ming, vice president of the company, on October 17 Yu Ming resigned as vice president of the company due to the change of work After his resignation, Yu Ming no longer held the post of China Resources 39 As of the date of this announcement, Yu Ming did not hold the shares of China Resources 39 On October 21, Shi Zhongyuan, a director of Anhui yuanhetang Pharmaceutical Co., Ltd., resigned, saying that he no longer held the post of director of Anhui yuanhetang Pharmaceutical Co., Ltd for personal reasons On October 23, Eli Lilly announced that Enrique conterno, vice president of the company and head of global diabetes business, would resign at the end of the year The replacement of conterno has also been confirmed Mike Mason, head of Lilly's insulin manufacturing department, will take office on January 1, 2020 Some foreign media pointed out that the resignation of conterno may be due to the instability and development of Lilly's diabetes business over the years On October 26, Jiangsu Wuzhong Industry Co., Ltd issued a notice announcing the resignation of Wang Xiaogang, President (General Manager) In view of the announcement of Wang Xiaogang's resignation and the announcement of Jiangsu Wuzhong third quarterly on the same day, there may be a close relationship between the two According to the previous statistics of an institution, from January to September 2019, at least 76 senior executives have resigned, including the chairman, general manager, deputy general manager, etc., involving well-known pharmaceutical enterprises at home and abroad such as Novartis, Merck, MSD, Taiji group, Lizhu group, etc So far, nearly 90 senior drug companies have left In addition to the frequent layoffs of senior executives, pharmaceutical companies themselves are also in the process of new slimming On October 23, Novartis announced that it would further push forward productivity contraction and cut 320 jobs in Ireland The production facility in ringaskiddy, Ireland, will be closed by mid-2022, with 240 job cuts at its "active pharmaceutical ingredients (API)" plant to consolidate its API business; and 80 job cuts at the park's "global services" sector, with the remaining "global services" employees planned to move to European and Asian centers by 2021 Both departments are part of Novartis' technology operations, and layoffs will help streamline organizational structure and focus resources on innovation and R & D Similarly, Alkermes, an Irish biopharmaceutical company, said on Wednesday that it would lay off 160 people and cut future employment and expenses in order to restructure the company and prevent losses The biopharmaceutical company has about 2300 employees, and the restructuring will affect about 7% of its employees In addition, it is reported that MSD USA will also cut its staff from January 3, 2020, and the positions to be eliminated will mainly focus on the sales and headquarters business team Pamela Eisele, a spokeswoman for MSD, said recently that "some of the affected employees can apply for positions in other departments of the company, and those who are dismissed will receive" full separation treatment " On the whole, cost cutting, focusing on advantageous business and strategic structure adjustment have become the main reasons for the announced layoffs of these pharmaceutical enterprises But in a deeper level, behind the frequent personnel changes of pharmaceutical enterprises, there are more dramatic changes in the industrial pattern and the reshaping of the market structure It can be predicted that in the future, the competition in the pharmaceutical market in China and even in the world will be more fierce, and the change of senior managers among pharmaceutical enterprises will not stop After all, in the stage of business transformation, each pharmaceutical enterprise is building a new governance structure, developing a new industrial structure to adapt to the new environment, and establishing a new leadership will be a necessary step in the development process.